Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
28 mars 2024 16h15 HE
|
Unicycive Therapeutics, Inc.
– Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose...
Diabetic Kidney Disease Global Market Research Report 2024
25 mars 2024 11h05 HE
|
Research and Markets
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The diabetic kidney disease market size...
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
25 mars 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
American Kidney Fund Launches Phosphorus Management Education and Awareness Campaign
19 mars 2024 09h15 HE
|
American Kidney Fund
ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as...
American Kidney Fund Convenes Nation’s Kidney Community for 2024 Kidney Action Week™ March 18-22
18 mars 2024 09h47 HE
|
American Kidney Fund
ROCKVILLE, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) kicks off its fifth annual Kidney Action Week™, the nation’s only free online conference that draws patients,...
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Against Kidney Disease
15 mars 2024 08h59 HE
|
American Kidney Fund
ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate...
Unicycive Announces $50 Million Private Placement
14 mars 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
13 mars 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
– Promising Preclinical Results in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 13, 2024 ...
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
07 mars 2024 16h12 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
04 mars 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...